trastuzumab deruxtecan (n=373) vs. chemotherapy (n=184)
randomized controlled trial
trastuzumab deruxtecan
physician’s choice of chemotherapy
metastatic/advanced - breast cancer (mBC)
Low expression of HER2 was defined as a score of 1 on immunohistochemical [IHC] analysis or as an IHC score of 2 and negative results on in situ hybridization